In the trial, the company will evaluate the safety and efficacy of Prochymal in conjunction with standard of care in improving heart function in patients who experienced their first heart attack.
In total, Osiris has recruited around 220 patients from 33 leading clinical centers in the United States and Canada.
Osiris Therapeutics senior vice president Lode Debrabandere said they look forward to following their progress and collecting high quality data on the safety and efficacy of Prochymal in this significant indication.